Hyderabad-based Dr. Reddy’s Laboratories has completed the purchase of worldwide exclusive intellectual property rights for Fondaparinux sodium, its generic anti-coagulant drug, from its Australian partner, Alchemia Limited.
Earlier, the company had signed a term sheet for this transaction in September, 2015.
Alchemia’s shareholders approved the sale of Fondaparinux at the Company’s annual general meeting held on 10 November 2015, post which Dr. Reddy’s and Alchemia have executed a purchase and sale agreement, together with various patent assignment deeds.
Alchemia has received US$17.5 million from Dr. Reddy’s as consideration for the sale. The agreement is effective July, 2015.
Fondaparinux is a generic version of the anticoagulant drug Arixtra®. Arixtra® is approved in the US and Europe for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and is also indicated for the prevention of DVT after major surgery, such as knee and hip replacement. Fondaparinux is recommended by the American College of Chest Physicians and received the European Society of Cardiology’s highest recommendation for use in acute coronary syndrome. fii-news.com
